Business and InvestmentHigh importance
Isomorphic Labs, spun out of Google DeepMind, raises $5 billion to take AI-designed drugs to clinical trials
Isomorphic Labs, the AI drug-discovery company spun out of DeepMind in 2021, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and participation from all existing backers, such as GV, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company, which builds on the work behind AlphaFold, says it has obtained “positive preclinical results” in oncology and immunology and has deals with Eli Lilly, Novartis and Johnson & Johnson. The money, which comes after a $2.1 billion Series B in May, will go to its drug-design engine and to new areas of medicine. The valuation was not disclosed; Bloomberg reported this month that the target was $50 billion.
Published in edition no. 36 of Noticiário do Joãozinho ·
Translated by Joãozinho AI from the original Brazilian Portuguese edition. Facts, numbers and sources are the same as in the original; quotes, video titles and source names stay in their original language. Read the original in Portuguese
Original source
https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/